MDxHealth (MDXH) Expected to Announce Earnings on Thursday

MDxHealth (NASDAQ:MDXH) is projected to announce its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to announce earnings of ($0.1934) per share and revenue of $26.1440 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:30 PM ET.

MDxHealth (NASDAQ:MDXH) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The company had revenue of $23.90 million for the quarter, compared to analyst estimates of $30.89 million. On average, analysts expect MDxHealth to post $-1 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

MDxHealth Stock Performance

MDXH stock opened at $0.45 on Tuesday. The stock has a market capitalization of $22.47 million, a P/E ratio of -0.70 and a beta of 1.42. MDxHealth has a one year low of $0.40 and a one year high of $5.33. The company has a 50 day moving average price of $0.48 and a two-hundred day moving average price of $1.86.

Hedge Funds Weigh In On MDxHealth

Hedge funds have recently made changes to their positions in the business. XTX Topco Ltd boosted its position in MDxHealth by 220.0% during the 4th quarter. XTX Topco Ltd now owns 40,860 shares of the company’s stock worth $146,000 after purchasing an additional 28,090 shares during the period. Millennium Management LLC raised its position in MDxHealth by 328.3% in the fourth quarter. Millennium Management LLC now owns 116,831 shares of the company’s stock valued at $417,000 after purchasing an additional 89,553 shares during the period. Balyasny Asset Management L.P. purchased a new position in MDxHealth in the fourth quarter valued at about $68,000. 683 Capital Management LLC acquired a new position in shares of MDxHealth during the fourth quarter worth about $384,000. Finally, Lazard Asset Management LLC acquired a new position in shares of MDxHealth during the fourth quarter worth about $83,000.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on MDXH. BTIG Research decreased their price objective on MDxHealth from $7.00 to $4.00 and set a “buy” rating on the stock in a report on Thursday, May 14th. William Blair lowered MDxHealth from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Lake Street Capital reduced their target price on MDxHealth from $9.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, May 14th. TD Cowen reissued a “buy” rating and issued a $1.50 price target (down from $7.00) on shares of MDxHealth in a research note on Thursday, May 14th. Finally, Wall Street Zen cut MDxHealth from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $3.50.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.